

Prof. Christine Rouzioux for the OPP-ERA Consortium : Solthis, ANRS, Expertise France & Sidaction

## Open Polyvalent Platforms (OPP)


constitute an innovative technology for VLT and might help to increase the market with new suppliers.




**DNA/RNA Extractor**      **Thermocycler Real time PCR**      **HIV-1 amplification Assay**

The **Platforms** are **Open** to several machine suppliers **Polyvalent**: they could be also used for EID (Early Infant Diagnosis), HBV, HCV, Tuberculosis....etc

## Example of the follow up of weekly reports: good intra and inter-laboratories reproducibility




## High Proportion of treated patients with viral success (1st test)



## OBJECTIVES of the OPP-ERA Project

- **IMPACT ON PUBLIC HEALTH:** Reinforcing access to HIV viral load and early diagnosis in targeted countries, complementary to integrated platforms and POC
- **IMPACT ON THE MARKET:** Stimulating competition on HIV viral load testing market: new manufacturers and technologies through the promotion of OPP



**4 Countries**  
Burundi  
Cameroun,  
Ivory Coast  
Guinea

## PHASE 1 (March 2013-July 2016) Results

- 7 laboratories were equipped.
- Training over 220 clinicians and lab technicians
- Labs quickly became functional
- They now produce quality results, even in those who have never done Molecular Biology
- Success in implementing viral load Despite major political and epidemic difficulties (political instability in Burundi; Ebola epidemic in Guinea)
- Demonstration that OPP facilities are suitable for LIMC: few maintenance issues
- Increase in commodities quantity in the OPP-ERA lab
- 70,000 viral loads tests performed since August 2014.
- Good results of the Quality program.

## Conclusions

- Labs are working well.
- OPP are well adapted to West and Central African countries
- Viral success >73%, with 87.4% in Burundi
- Report of a low VL prescription of by Physicians
- Preliminary analysis of barriers: Physicians Need time for adaptation to many changes (new WHO recommendations, various access and stroke of second line drugs)

## PHASE 2 (Aug 2016 – Aug 2019) : Objectives and perspectives

- To Demonstrate optimal use of platforms through scale-up and decentralization of OPPs in the four Project countries
- New Targets of 14 labs and >300 000 VL
- To demonstrate OPP value on Polyvalence for Tuberculosis and HBV
- To implement routine use of EID and DBS
- To strengthen the Quality Assurance Plan
- To increase demand creation for VL testing from clinicians and patients
- **To develop new adherence programs integrating**
- To implement task shifting for VL prescription (nurses and pharmacists)
- To strengthen the role of the Civil Society
- To implement transition to National Authorities in the four countries.
- To provide evidence related to health economy
  - Conduct cost-effectiveness studies
  - Develop a costing tool and train national key staff
  - Conduct a global market analysis
  - Facilitate introduction of new suppliers with lower unit costs.

This work has been mainly produced with efficiency and enthusiasm by the teams in CEDRES and CEPREF in Abidjan, Ivory Cost, in LNPS and Donka Hopsital in Conakry, Guinea, in the ANSS Bujumbura, Burundi and in Centre Pasteur de Garoua et Laquintinie Hospital in Douala Cameroun. Many thanks to Physicians and Patients to the Parisian Teams in Solthis, ANRS, Expertise France and Sidaction and to UNITAID for funding.